Acknowledgement
This study used the National Health Information Database (NHIS-2019-1-662) of the National Health Insurance Service (NHIS).
References
- World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment. Drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020.
- World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization; 2021.
- Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, Lonnroth K, et al. MDR tuberculosis: critical steps for prevention and control. N Engl J Med 2010;363:1050-8. https://doi.org/10.1056/NEJMra0908076
- Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017; Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet 2018;392:821-34. https://doi.org/10.1016/S0140-6736(18)31644-1
- Van Deun A, Decroo T, Piubello A, de Jong BC, Lynen L, Rieder HL. Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. Int J Tuberc Lung Dis 2018;22:239-45. https://doi.org/10.5588/ijtld.17.0660
- Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013;42:156-68. https://doi.org/10.1183/09031936.00134712
- Lee M, Han J, Kim YR, Kwak N, Kim JH, Park O, et al. Multidrug-resistant tuberculosis in South Korea: a retrospective analysis of national registry data in 2011-2015. Int J Tuberc Lung Dis 2019;23:850-7. https://doi.org/10.5588/ijtld.18.0658
- Lee T, Lee SJ, Jeon D, Lee HY, Kim HJ, Kang BH, et al. Additional drug resistance in patients with multidrug-resistant tuberculosis in Korea: a multicenter study from 2010 to 2019. J Korean Med Sci 2021;36:e174.
- World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020.
- Korea Disease Control and Prevention Agency. Annual report on the notified tuberculosis in Korea, 2021 [Internet]. Cheongju: KDCA; 2019 [cited 2023 Jun 12]. Available from: https://tbzero.kdca.go.kr/tbzero/board/boardView.do?leftMenuId=3¶mMenuId=34&boardSeq=7528&crudType=R.
- World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization; 2018.
- Jeong D, Kang HY, Kim J, Lee H, Yoo BN, Kim HS, et al. Cohort profile: Korean tuberculosis and post-tuberculosis cohort constructed by linking the Korean National Tuberculosis Surveillance System and National Health Information Database. J Prev Med Public Health 2022;55:253-62. https://doi.org/10.3961/jpmph.21.635
- World Health Organization. Definitions and reporting framework for tuberculosis: 2013 revision. Geneva: World Health Organization; 2013.
- World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: World Health Organization; 2011.
- World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014.
- World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis: 2016 update. Geneva: World Health Organization; 2016.
- Kwak N, Kim HR, Yoo CG, Kim YW, Han SK, Yim JJ. Multidrug-resistant tuberculosis over 20 years at a referral hospital in South Korea: trends and outcomes. Int J Tuberc Lung Dis 2019;23:174-80. https://doi.org/10.5588/ijtld.18.0295
- Kang Y, Jo EJ, Eom JS, Kim MH, Lee K, Kim KU, et al. Treatment outcomes of patients with multidrug-resistant tuberculosis: comparison of pre- and post-public-private mix periods. Tuberc Respir Dis (Seoul) 2021;84:74-83. https://doi.org/10.4046/trd.2020.0093
- Hwang H, Kang H, Kwon YS, Jeon D, Shim TS, Yim JJ. Outcomes of multidrug-resistant tuberculosis treated with bedaquiline or delamanid. Clin Infect Dis 2021;73:1362-9. https://doi.org/10.1093/cid/ciab304
- World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019.
- Tahseen S, Van Deun A, de Jong BC, Decroo T. Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know? J Antimicrob Chemother 2021;76:831-5. https://doi.org/10.1093/jac/dkaa489
- Cegielski JP, Chan PC, Lan Z, Udwadia ZF, Viiklepp P, Yim JJ, et al. Aminoglycosides and capreomycin in the treatment of multidrug-resistant tuberculosis: individual patient data meta-analysis of 12 030 patients from 25 countries, 2009-2016. Clin Infect Dis 2021;73:e3929-36. https://doi.org/10.1093/cid/ciaa621
- Lee H, Ahn S, Hwang NY, Jeon K, Kwon OJ, Huh HJ, et al. Limited effect of later-generation fluoroquinolones in the treatment of ofloxacin-resistant and moxifloxacin-susceptible multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2018;62:e01784-17.
- Jo KW, Lee SD, Kim WS, Kim DS, Shim TS. Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2014;18:39-43. https://doi.org/10.5588/ijtld.13.0307
- World Health Organization. Framework for the engagement of all health care providers in the management of drug resistant tuberculosis. Geneva: World Health Organization; 2015.